Table 3.

Studies evaluating regression of CLD but not evaluating portal hypertension

Drug (drug class)	Effects
Enoxaparin (anticoagulant) [122]	↓ probability of PVT development ↑ survival *A trial with rivaroxaban, another anticoagulant, is currently ongoing [123]
Liraglutide (GLP-1 analog) [124]	↓ progression of fibrosis (but no significant improvement) NASH resolution
Selonsertib (ASK1 inhibitor) [125]	No effect on fibrosis
Cenicriviroc (CCR2 and CCR5 antagonist) [126]	Improvement in fibrosis (effect more pronounced on patients with more advanced disease) ↓ in collagen area by morphometry, ↓ in systemic inflammation biomarkers *currently tested as monotherapy in a phase 3 trial (AURORA) or in combination with the FXR agonistc(TANDEM trial) in F2/3 NASH patients [127, 128]
Pioglitazone (PPAR γ agonist) and vitamin E [129]	Improvement in NASH (vitamin E but not pioglitazone) No improvement in fibrosis for any of the trial drugs
Lanifibranor (PPAR α/δ/γ agonist) [130]	NASH resolution Improvement in fibrosis
G-CSF or G-CSF followed by CD133 + cells (cell therapy) [131]	No improvement in liver function tests, non-invasive fibrosis markers, MELD or CPS

PVT portal vein thrombosis, GLP-1 glucagon-like peptide-1, ASK1 apoptosis signal-regulating kinase 1, CCR C-C chemokine receptor, FXR farnesoid X receptor, PPAR peroxisome proliferator-activated receptors, G-CSF granulocyte-colony stimulating factor, CD cluster of differentiation